Pathways to new treatments for heart failure take time—as long as four decades for two now accepted therapies. So, new ...

Exegenesis Bio, a clinical stage global gene therapy company is pleased to announce that US FDA has granted Orphan Drug Designation ("ODD") to EXG110, a novel gene therapy for Fabry disease, a rare ...

The different types of biomaterials and their classifications (inert, active and resorbable) are defined and key properties ...

Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered ...